DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Breast Cancer Pipeline Report

• DelveInsight’s Metastatic Breast Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
• The leading companies working in the Metastatic Breast Cancer Market include Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc.., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. Ltd, and others.
• Promising Metastatic Breast Cancer Pipeline Therapies in the various stages of development include Patritumab Deruxtecan, Ixabepilone, Carboplatin, Alpelisib, Tucatinib, Fulvestrant, and others.
• November 2023: Hoffmann- La Roche announced a study of Phase 3 clinical trials for Inavolisib and Phesgo. This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
• November 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, and Vinorelbine. The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician’s choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC). Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy.
• November 2023: Ambrx Inc. announced a study of Phase 2 clinical trials for ARX788. A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
• October 2023: Criterium Inc. announced a study of Phase 1 & 2 clinical trials for Alpelisib, Tucatinib, and Fulvestrant. Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer. This study is a multicenter, single arm, open-label, run-in phase Ib safety cohort with immediate roll over to a phase II clinical trial that will test the combination therapy of tucatinib with alpelisib in subjects with PIK3CA-mutant HER2+ locally advanced unresectable or metastatic breast cancer. Patients with PIK3CA-mutant HR-/HER2+ and HR+/HER2+ breast cancer may enroll, the latter cohort will receive concomitant treatment with standard doses of fulvestrant to block HR signaling. In phase Ib part, we will confirm the tolerability of tucatinib and alpelisib combination and determine the maximum tolerated dose (MTD). In phase II part, we will expand the testing of this drug combination at MTD to determine the PFS rate.

 

Request a sample and discover the recent advances in Metastatic Breast Cancer Treatment Drugs @ Metastatic Breast Cancer Pipeline Report

 

In the Metastatic Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Metastatic Breast Cancer Overview

Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. The symptoms of metastatic breast cancer can vary greatly depending on the location of the cancer. This section covers the symptoms of breast cancer that has spread to the bone, lung, brain, and liver, and the tests used to diagnose metastatic breast cancer.

 

Find out more about Metastatic Breast Cancer Therapeutics Assessment @ Metastatic Breast Cancer Preclinical and Discovery Stage Products

 

Metastatic Breast Cancer Emerging Drugs Profile

• Giredestrant: Roche
• Disitamab Vedotin: RemeGen
• EndoTAG®-1 (SB05): SynCore Biotechnology
• Stenoparib (2X-121): Allarity Therapeutics

 

Metastatic Breast Cancer Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Metastatic Breast Cancer. The Metastatic Breast Cancer companies which have their Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Roche.

 

DelveInsight’s Metastatic Breast Cancer Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Metastatic Breast Cancer Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Metastatic Breast Cancer Pipeline Therapies @ Metastatic Breast Cancer Clinical Trials Assessment

 

Scope of the Metastatic Breast Cancer Pipeline Report

• Coverage- Global
• Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Breast Cancer Companies- Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc.., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. Ltd, and others.
• Metastatic Breast Cancer Pipeline Therapies- Patritumab Deruxtecan, Ixabepilone, Carboplatin, Alpelisib, Tucatinib, Fulvestrant, and others.

 

Dive deep into rich insights for new drugs for Metastatic Breast Cancer Treatment, Visit @ Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Giredestrant: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Stenoparib – Allarity Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ARV-471: Arvinas
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Breast Cancer Key Companies
21. Metastatic Breast Cancer Key Products
22. Metastatic Breast Cancer- Unmet Needs
23. Metastatic Breast Cancer- Market Drivers and Barriers
24. Metastatic Breast Cancer- Future Perspectives and Conclusion
25. Metastatic Breast Cancer Analyst Views
26. Metastatic Breast Cancer Key Companies
27. Appendix

 

For further information on the Metastatic Breast Cancer Pipeline therapeutics, reach out to Metastatic Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services